UPADACITINIB (Rinvoq®)

Clinical Indication

Active psoriatic arthritis after inadequate response to DMARDs

Comments

Comments: In line with NICE TA768

Date of classification

April 2022

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.